Unlocking Persistent Motivation & Extreme Resilience | Ross Edgley

Episode Overview

• Dr. Rhys and Dr. Shai Efrati discuss how manipulating cellular oxygen sensing via the Hypoxia-Inducible Factor (HIF) pathway can reverse aging biomarkers, regenerate damaged brain and vascular tissue, and treat chronic neurological and metabolic conditions.
• The episode traces the science from the 2019 Nobel Prize discovery of HIF-1alpha and high-altitude genetic adaptations to the "hyperoxic-hypoxic paradox," a clinical protocol that uses high-pressure oxygen fluctuations to trick cells into regenerating without starving them of energy.
• Dr. Efrati details clinical trial evidence showing how specific hyperbaric oxygen therapy (HBOT) protocols clear senescent cells, lengthen telomeres, and repair microvascular damage in stroke, traumatic brain injury, early Alzheimer's, PTSD, fibromyalgia, Long COVID, and erectile dysfunction.
• The conversation concludes by examining safety contraindications, the limitations of consumer "soft-shell" chambers, and accessible ways to trigger the HIF pathway outside of a clinic using high-intensity interval training (HIIT), breathwork, and intermittent hypoxic training.

Key Concepts

• The HIF Pathway and Oxygen Sensing: Discovered by 2019 Nobel laureates William Kaelin, Peter Ratcliffe, and Gregg Semenza, Hypoxia-Inducible Factor (HIF-1alpha) is a master regulator of cellular adaptation. Under normal oxygen conditions (normoxia), enzymes called prolyl hydroxylases (PHDs) use oxygen to tag HIF-1alpha for immediate destruction by the VHL protein complex. When oxygen drops, PHD enzymes stop working, allowing HIF-1alpha to accumulate, enter the nucleus, and switch on over 100 genes responsible for red blood cell production (via EPO), new blood vessel growth (via VEGF), glucose metabolism, inflammation control, and stem cell mobilization.
• High-Altitude Evolutionary and Health Adaptations: Populations living at altitudes between 1,500 and 2,500 meters (such as in Switzerland, Colorado, and the Andes) experience chronic mild activation of the HIF pathway, which is associated with lower rates of cardiovascular mortality, obesity, and certain cancers compared to sea-level populations. At extreme elevations like the Tibetan Plateau (4,000 meters average elevation with roughly 40% less oxygen), indigenous Tibetans rely on an EPAS1 gene variant (encoding HIF-2alpha) inherited from Denisovans over 40,000 years ago, allowing them to extract oxygen efficiently without overproducing red blood cells and risking strokes.
• The Hyperoxic-Hypoxic Paradox: Cells do not measure absolute oxygen levels; they sense relative fluctuations (the delta). By placing a patient in a chamber at 2.0 Atmospheres Absolute (ATA) breathing 100% oxygen, dissolved blood oxygen increases 10- to 15-fold. When the patient removes the oxygen mask to breathe normal 21% chamber air, the sudden drop is interpreted by cells as severe hypoxia. This triggers HIF, VEGF, and stem cell proliferation while the tissues remain flooded with the abundant oxygen and ATP energy required to actually build new tissue and blood vessels (angiogenesis).
• Business Ties Context: Throughout the discussion of clinical HBOT protocols, note that Dr. Shai Efrati is the Founder and Director of the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center (where the discussed protocols were developed and tested) and serves as Chair of the Medical Advisory Board at Aviv Scientific (Aviv Clinics), which commercially provides these specific HBOT protocols.
• Antioxidant Net Protection via Nrf2: During the hyperoxic phase of treatment, increased production of reactive oxygen species (ROS) triggers a parallel surge in endogenous antioxidants via the Nrf2 pathway. Because endogenous antioxidants have a longer biological half-life than ROS, cycling back to normal oxygen leaves the cells in a net protective antioxidant state.
• Telomere Lengthening via Cellular Replacement: In a prospective clinical trial of 35 healthy, independent adults aged 64 and older undergoing 60 HBOT sessions (with no diet, lifestyle, or medication changes), telomere length in peripheral blood mononuclear cells (PBMCs) increased by more than 20% on average (ranging from roughly 20% to 38% depending on cell type, with B cells showing the largest increase), while senescent T-helper and cytotoxic T-cells dropped by 10% to 37%. This does not happen because existing old telomeres are stretched; rather, the protocol clears worn-out senescent cells via apoptosis and autophagy while stimulating bone marrow stem cells (which naturally possess long telomeres) to proliferate and replace them with fresh immune cells. Skin biopsies from aging patients undergoing the 60-session protocol also showed reduced senescent cells, increased elastic fiber length, increased collagen density, and new microvascular blood vessels in the dermis.
• The "Stunned" Metabolic Zone in Brain Injuries: After a stroke or Traumatic Brain Injury (TBI), brain tissue is not simply divided into healthy tissue and dead (necrotic) tissue. There is a third zone (the chronic penumbra) where neurons receive just enough oxygen to avoid necrosis and stay alive, but lack the ATP energy required to fire action potentials. Because standard anatomical MRI scans cannot detect this metabolic dysfunction, specialized perfusion MRI or SPECT imaging is required to visualize these recoverable wounds.
• Microvascular Origins of Alzheimer's and Dementia: Only about 30% of dementia patients have pure Alzheimer's pathology; most suffer from mixed vascular pathology. Age-related loss of microvasculature causes local hypoxia and neuroinflammation, which subsequently drives amyloid plaque accumulation. In 5XFAD transgenic mice and human pilot studies on Mild Cognitive Impairment (MCI), HBOT reduced amyloid plaques, resolved vascular hypoxia, improved cerebral blood flow, and improved memory scores. However, Dr. Efrati warns that HBOT cannot revive necrotic, atrophic neurons in late-stage Alzheimer's; intervention must occur at the MCI or mild stage.
• PTSD and Fibromyalgia as Biological Brain Wounds: Functional brain imaging in military veterans with treatment-resistant PTSD reveals metabolic and structural wounds in the frontal lobe, hippocampus, and amygdala. Repairing these networks via 60 HBOT sessions restores the frontal lobe's ability to regulate the amygdala. Similarly, clinical trials show fibromyalgia is a central sensitization syndrome caused by metabolic wounds in pain-processing brain regions (triggered by physical trauma, emotional trauma, or viral infections like Epstein-Barr), which resolves when brain metabolism is repaired.
• Microvascular Repair in Long COVID and Erectile Dysfunction: In a randomized, sham-controlled, double-blind trial published in Scientific Reports, 40 HBOT sessions significantly improved Long COVID brain fog (dysexecutive function), fatigue, pain, psychiatric symptoms, and cardiac function (global longitudinal strain) by repairing viral endothelial damage in small blood vessels. In men with chronic non-surgical erectile dysfunction where PDE5 inhibitors (like Viagra) fail due to lost capillary beds, HBOT induced angiogenesis in the corpus cavernosum, restoring spontaneous erectile function in up to 80% of participants.
• Tumor Microenvironments and Oxygen: Solid tumors thrive, mutate, and metastasize in hypoxic microenvironments that drive aggressive VEGF signaling. Oxygenating tissue does not cause cancer or accelerate tumor growth; instead, it makes the tumor microenvironment less aggressive, though active oncology patients are generally excluded from standard longevity HBOT clinics unless participating in specific radiation-sensitization protocols.
• Pharmacological vs. Physiological HIF Activation: FDA- and EMA-approved PHD inhibitors (such as Roxadustat and Daprodustat) stabilize HIF pharmacologically to boost endogenous EPO and treat anemia in chronic kidney disease. However, continuous systemic pill-based HIF activation carries risks of thrombosis, pulmonary hypertension, and theoretical tumor promotion, whereas intermittent physiological fluctuations (via HBOT or exercise) avoid chronic systemic overactivation.

Quotes

• At 0:01:28 - "Under normal oxygen conditions, your cells are constantly making a protein called HIF-1alpha, and just as quickly destroying it. Enzymes called prolyl hydroxylases, or PHDs, use oxygen molecules to tag HIF-1alpha for destruction within minutes of it being made." - Dr. Rhys explaining the baseline cellular mechanism discovered by the 2019 Nobel Prize winners.
• At 0:05:31 - "What we understand today is that at the cellular level, our body doesn't actually sense the absolute value of oxygen. What we sense is the fluctuation, the delta, the change." - Dr. Shai Efrati introducing the foundational rule of cellular oxygen sensing.
• At 0:07:36 - "When we take a person and we put him in a hyperbaric chamber, we increase the dissolved oxygen in the blood by 10 to 15 fold. And then when we ask him to take the mask off, we take him from very high oxygen back to normal oxygen. The cells sense this decline from high to normal as hypoxia, even though there is surplus of oxygen in the tissue." - Dr. Efrati explaining how the chamber tricks cells into triggering hypoxia pathways safely.
• At 0:08:30 - "We call it the hyperoxic-hypoxic paradox. We fool the body to think that it is in hypoxia while actually providing it with extra oxygen." - Dr. Efrati defining the core therapeutic mechanism of his clinical protocols.
• At 0:13:52 - "If you induce hypoxia, true hypoxia, you will have the signal, HIF will go up, but you will not have the energy, the ATP, to build the tissue. With the hyperoxic-hypoxic paradox, you get both the signal to build and the fuel to do the construction." - Dr. Efrati clarifying why true oxygen deprivation fails to regenerate aging or damaged tissue as effectively as hyperoxic fluctuations.
• At 0:16:07 - "What is called mild hyperbaric, or the soft bags that go up to 1.3 atmosphere, they do not induce the hyperoxic-hypoxic paradox. They do not induce stem cell proliferation, and they do not induce angiogenesis." - Dr. Efrati distinguishing consumer soft-shell chambers from hard-shell medical chambers.
• At 0:19:46 - "In our protocol, we go to 2 atmospheres absolute for 90 minutes, five days a week, for 60 sessions. Inside the chamber, every 20 minutes you take the oxygen mask off for five minutes to create those repeated fluctuations." - Dr. Efrati detailing the exact dosing parameters of the Aviv/Sagol regenerative protocol.
• At 0:22:07 - "We saw for the first time in humans that we can actually elongate telomeres by more than 20 percent, and we can reduce the number of senescent cells, the zombie cells, by up to 37 percent." - Dr. Efrati summarizing the primary outcomes of his clinical trial on healthy aging adults aged 64 and older.
• At 0:24:32 - "It is not that we took an old cell with a short telomere and elongated it. What happens is that we clear the old senescent cells, and at the same time we stimulate the stem cells in the bone marrow, which have long telomeres, to proliferate and produce new young cells." - Dr. Efrati correcting a common misconception about how HBOT increases average PBMC telomere length.
• At 0:27:47 - "In the brain after a stroke or traumatic brain injury, it's not just dead tissue and healthy tissue. There is a third zone, stunned tissue, where neurons have just enough oxygen to stay alive, so they don't die, but they don't have enough energy to fire and function." - Dr. Efrati explaining why neurological recovery is possible years or decades after an initial brain insult.
• At 0:29:15 - "If you do a regular MRI, which is an anatomical imaging, that tissue looks normal. Only when you do metabolic or perfusion imaging, like SPECT or unique MRI sequences, you suddenly see the wound." - Dr. Efrati highlighting why standard brain scans miss chronic metabolic brain injuries.
• At 0:34:28 - "When we look at Alzheimer's disease, in most cases it starts as a vascular problem. With aging, we lose the small blood vessels, the microvasculature, which leads to local hypoxia, neuroinflammation, and then the accumulation of amyloid plaques." - Dr. Efrati framing cognitive decline as a microvascular oxygen-delivery failure.
• At 0:35:30 - "If a patient comes to us with severe Alzheimer's where the brain tissue is already necrotic and atrophic, we cannot revive dead tissue. We have to intervene at the stage of mild cognitive impairment, when the tissue is still metabolically dysfunctional but alive." - Dr. Efrati hedging on the limits of HBOT in advanced neurodegenerative disease.
• At 0:36:35 - "PTSD is not just a psychological issue; it is a biological wound in the brain. We can see it on metabolic imaging in the frontal lobe, the hippocampus, and the amygdala." - Dr. Efrati explaining the physical pathology underlying treatment-resistant PTSD in military veterans.
• At 0:38:57 - "Very often, around the third or fourth week of treatment, PTSD patients start to recover repressed memories that were completely inaccessible for decades, because we are physically reconnecting those neural networks." - Dr. Efrati describing a clinical phenomenon that requires psychological support during HBOT for trauma.
• At 0:40:26 - "In fibromyalgia, the problem is not in the muscles or the joints; the problem is in the pain-processing centers in the brain. Once you repair the brain metabolism in those areas, the chronic pain resolves." - Dr. Efrati explaining how central sensitization in fibromyalgia responds to brain-targeted oxygen therapy.
• At 0:42:02 - "The COVID virus injures the endothelium, the inner lining of the very small blood vessels, creating microvascular ischemia in the brain and in the heart, which is why Long COVID patients suffer from severe brain fog and fatigue." - Dr. Efrati detailing the pathology treated in his randomized, sham-controlled Long COVID trial.
• At 0:43:35 - "Drugs like Viagra need existing blood vessels to dilate. If you lost the microvasculature because of aging or diabetes, Viagra won't work. By inducing angiogenesis and building new blood vessels, up to 80 percent of these men regained natural erectile function." - Dr. Efrati explaining why building new capillary beds succeeds where nitric oxide vasodilators fail.
• At 0:46:23 - "Cancer loves hypoxia. Hypoxia is the main driver for tumor aggressiveness and metastasis. Oxygenating the tissue does not promote cancer; in fact, it makes the tumor microenvironment less aggressive." - Dr. Efrati addressing the safety concern regarding whether HBOT promotes tumor growth.
• At 0:49:16 - "When you do high-intensity interval training, you bring the muscle to anaerobic metabolism, to local hypoxia, and then you rest and recover. That fluctuation is the exact same biological principle." - Dr. Efrati connecting clinical chamber protocols to free, accessible exercise physiology.

Takeaways

• Use High-Intensity Interval Training (HIIT) for Free HIF Activation: Replicate the hyperoxic-hypoxic fluctuation naturally by pushing muscles to their local anaerobic lactate threshold (creating local hypoxia) and resting completely between intervals so incoming oxygen can fund mitochondrial biogenesis and VEGF-driven vascular repair.
• Avoid Soft-Shell Chambers for Regenerative Goals: Do not rely on 1.3 ATA soft-shell "mild" chambers using oxygen concentrators if your goal is stem cell proliferation or angiogenesis; they only increase oxygen while you are inside and carry risks of microbial contamination, zipper/structural burst failures, and fire hazards if oxygen builds up inside the bag.
• Follow the Exact Clinical Protocol for Tissue Regeneration: If pursuing medical HBOT for longevity or neurological repair, ensure the clinic uses a hard-shell chamber at 2.0 ATA for 90 minutes, 5 days a week, for 60 total sessions (40 sessions for Long COVID), cycling between 20 minutes of 100% oxygen via a tight-fitting mask and 5 minutes of mask-off normal air (21% oxygen).
• Complete the Full 60 Sessions for Structural Repair: While circulating stem cells increase 3- to 8-fold by session 20 to 30, do not stop treatment early; completing the full 60 sessions is required to allow those mobilized stem cells to differentiate into new blood vessels and neurons.
• Request Metabolic Brain Imaging for Chronic Brain Wounds: If evaluating persistent post-stroke deficits, TBI, PTSD, or fibromyalgia, request SPECT or perfusion MRI scans rather than relying solely on standard anatomical MRIs, which miss metabolically "stunned" tissue.
• Intervene Early at the Mild Cognitive Impairment (MCI) Stage: Seek microvascular interventions like HBOT or aggressive cardiovascular conditioning at the earliest signs of cognitive decline or MCI, before ischemic brain tissue progresses to irreversible necrosis and atrophy.
• Arrange Psychological Support During PTSD Chamber Therapy: Ensure patients undergoing HBOT for treatment-resistant PTSD have professional mental health support in place, especially around weeks 3 and 4 when physical reconnection of hippocampal and cortical networks frequently causes decades-old repressed memories to resurface.
• Screen for Strict HBOT Contraindications Before Starting: Rule out untreated pneumothorax, active chest infections, severe COPD with air trapping (bullae), uncontrolled seizure disorders (due to central nervous system oxygen toxicity risk), and incompatible chemotherapy medications such as Bleomycin or Doxorubicin.
• Anticipate Temporary Vision Changes and Ear Pressure: Prepare for common transient side effects during a 60-session HBOT protocol, including middle ear barotrauma (managed by equalizing ear pressure) and temporary myopic shift (nearsightedness from oxygen affecting the eye's crystalline lens), which reverses completely within weeks of finishing therapy.
• Maintain Lifestyle Habits and Take Breaks Post-HBOT: Do not perform endless continuous HBOT sessions; take breaks after completing a protocol, and note Dr. Efrati's caveat that long-term durability of telomere and senescence improvements (1 to 5 years out) depends heavily on maintaining healthy sleep, diet, and exercise habits afterward.
• Consider Intermittent Hypoxic Training (IHT) as a Mid-Tier Option: Use mask-based systems that alternate breathing low-oxygen air (10% to 14% oxygen) with normal or hyperoxic air (IHHT) to stimulate HIF-1alpha and EPO, keeping in mind that systemic stem cell mobilization will be smaller than in a 2.0 ATA pressurized chamber.
• Use Breathwork for Acute Conditioning Rather Than Structural Angiogenesis: Practice breath-holding techniques (such as Wim Hof or Buteyko methods) to briefly drop blood oxygen saturation (SpO2) into the 70s or 80s for acute adrenaline spikes, splenic contraction, and transient HIF signaling, while recognizing Dr. Rhys's caveat that breathwork alone lacks clinical evidence for massive stem cell mobilization or structural brain repair.